Despite ≈2 decades since its discovery, the role of the 9p21.3 locus in cells of ... using unpaired t tests or 1-way ANOVA with Bonferroni correction. A complete list of primers used for qPCR is ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Locke, MD, explains how cema-cel is genetically engineered for patient benefit. ALPHA [NCT03939026] and ALPHA2 [NCT04416984] are single-arm, multicenter, open-label phase 1 studies designed to test ...

CAR T-cell therapy has significantly improved outcomes for B-ALL patients, but relapse still occurs in over 50% of cases, leaving many with limited treatment options. Ongoing research aims to ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers ...

Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...

Citation: Successful CAR-T cell therapy for end-stage multiple myeloma using advanced cellular product performed in Hong Kong (2025, March 27) retrieved 16 April 2025 from https://medicalxpress ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...